Zaki Seham Mahrous, Ahmed Hanan Samir, Yousif Monkez Motieh, Awad Eman Mohamed
Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt.
Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt.
Trop Med Infect Dis. 2022 Sep 5;7(9):230. doi: 10.3390/tropicalmed7090230.
In various genome-wide correlation studies, interleukin (IL)28B gene polymorphism has been strongly correlated with both the therapeutic and spontaneous mediated clearance of hepatitis C virus (HCV). Therefore, this study aimed to evaluate the genotype and allele frequency distributions of IL28B (rs12979860) in patients with chronic hepatitis C and assess the IL28B polymorphisms as predictors of sustained virological response to SOF-based therapy for HCV in Egyptian patients. This retrospective case-control study was conducted on 54 chronic HCV patients who completed treatment with SOF/DCV ± RBV for 12 weeks and responded to treatment with SVR12 (the responder group) as a control group, and 54 chronic HCV patients who completed treatment with SOF/DCV ± RBV for 12 weeks and did not respond to treatment and failed to achieve SVR12 (the non-responder group) as a case group. The CC genotype frequency of IL-28B (rs12979860) was greater in the responder group (51.9%). In contrast, the TT genotype frequency was higher in the non-responder group (48.1%) (p < 0.001), and the T allele significantly increased the risk of non-responses by 3.13 fold. Therefore IL-28B (rs12979860) SNP could be used as a genetic predictor of sustained virological response to SOF+DCV ± RBV-based HCV treatment in Egyptian patients.
在各种全基因组关联研究中，白细胞介素（IL）28B基因多态性与丙型肝炎病毒（HCV）的治疗性和自发性介导清除均密切相关。因此，本研究旨在评估慢性丙型肝炎患者中IL28B（rs12979860）的基因型和等位基因频率分布，并评估IL28B多态性作为埃及患者基于索磷布韦（SOF）治疗HCV获得持续病毒学应答的预测指标。本回顾性病例对照研究选取了54例完成12周SOF/达卡他韦（DCV）±利巴韦林（RBV）治疗且获得SVR12（持续病毒学应答12周，应答组）的慢性HCV患者作为对照组，以及54例完成12周SOF/DCV±RBV治疗但未应答且未实现SVR12（无应答组）的慢性HCV患者作为病例组。应答组中IL-28B（rs12979860）的CC基因型频率更高（51.9%）。相比之下，无应答组中TT基因型频率更高（48.1%）（p<0.001），且T等位基因使无应答风险显著增加3.13倍。因此，IL-28B（rs12979860）单核苷酸多态性可作为埃及患者基于SOF+DCV±RBV治疗HCV获得持续病毒学应答的遗传预测指标。
